| 2.99 -0.14 (-4.47%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.71 |
1-year : | 4.29 |
| Resists | First : | 3.18 |
Second : | 3.68 |
| Pivot price | 3.26 |
|||
| Supports | First : | 2.38 |
Second : | 1.98 |
| MAs | MA(5) : | 3.2 |
MA(20) : | 3.24  |
| MA(100) : | 2.92 |
MA(250) : | 4.6 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 11.8 |
D(3) : | 31.1 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 10.39 | Low : | 2.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ AVXL ] has closed above bottom band by 4.5%. Bollinger Bands are 17.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.09 - 3.12 | 3.12 - 3.14 |
| Low: | 2.91 - 2.94 | 2.94 - 2.96 |
| Close: | 2.95 - 3 | 3 - 3.02 |
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Fri, 28 Aug 2026
Anavex (AVXL) faces adverse opinion on internal controls - Stock Titan
Fri, 28 Aug 2026
AVXL: Net loss narrowed on lower R&D costs; strong cash, but leadership and compliance risks persist - TradingView
Fri, 28 Aug 2026
Former CEO exit flips Anavex (NASDAQ: AVXL) to quarterly profit - Stock Titan
Fri, 28 Aug 2026
Anavex (NASDAQ: AVXL) loss halves; cash seen funding into 2028 - Stock Titan
Fri, 28 Aug 2026
Anavex (AVXL) admits control weakness yet keeps Dec. 2025 numbers - Stock Titan
Tue, 25 Aug 2026
Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update - Anavex Life Sciences
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 93 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 40.6 (%) |
| Shares Short | 14,430 (K) |
| Shares Short P.Month | 14,230 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.5 % |
| Return on Equity (ttm) | -30.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -7.67 |
| PEG Ratio | 0 |
| Price to Book value | 2.28 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|